SCHEMBL4595845

SCHEMBL4595845

Clc1cc(Nc2ccccn2)nc(Cl)n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.48
MEN1 O00255 2/20 0.48
MAPK10 P53779 1/20 0.48
GFER P55789 1/20 0.48
CCNA2 P20248 1/20 0.46
CDK2 P24941 1/20 0.46
CCNA1 P78396 1/20 0.46
CDK5 Q00535 1/20 0.46
DYRK1A Q13627 1/20 0.46
CDK5R1 Q15078 1/20 0.46
KDR P35968 1/20 0.45
ABL1 P00519 1/20 0.45
PIM1 P11309 1/20 0.44
APAF1 O14727 1/20 0.43
TDP2 O95551 1/20 0.43
CDC25B P30305 1/20 0.43
CASP6 P55212 1/20 0.43
RCE1 Q9Y256 1/20 0.43
GRM5 P41594 2/20 0.43
TDP1 Q9NUW8 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4595367 0.83 KDR (0.47) KMT2AMEN1MAPK10GFERCCNA2
SCHEMBL18153286 0.80 KMT2A (0.51) KMT2AMEN1MAPK10GFERCCNA2
SCHEMBL4595519 0.80 KMT2A (0.42) KMT2AMEN1MAPK10GFERCCNA2
SCHEMBL2822274 0.79 KMT2A (0.52) KMT2AMEN1MAPK10GFERCCNA2
SCHEMBL29919717 0.77 MEN1 (0.50) KMT2AMEN1MAPK10GFERCDK2
SCHEMBL28936188 0.77 MEN1 (0.50) KMT2AMEN1MAPK10GFERCDK2
SCHEMBL221242 0.77 KMT2A (0.76) KMT2AMEN1MAPK10GFERKDR
SCHEMBL29391624 0.77 KMT2A (0.76) KMT2AMEN1MAPK10GFERKDR
SCHEMBL10639645 0.77 NFKB1 (0.55) KMT2AMEN1MAPK10GFERCCNA2
SCHEMBL14428206 0.77 KMT2A (0.55) KMT2AMEN1CDK2TDP1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080171742-A1 4-(Pyrid-2-Yl) Amino Substituted Pyrimidine as Protein Kinase Inhibitors ASRAZENECA (SE) 2008-07-17 US disclosed
EP-1871771-A1 4-(PYRID-2-YL) AMINO SUBSTITUTED PYRIMIDINE AS PROTEIN KINASE INHIBITORS AstraZeneca AB (SE) 2008-01-02 EP disclosed
WO-2006109026-A1 4-(PYRID-2-YL) AMINO SUBSTITUTED PYRIMIDINE AS PROTEIN KINASE INHIBITORS ASTRAZENECA AB (SE) 2006-10-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080171742-A1 4-(Pyrid-2-Yl) Amino Substituted Pyrimidine as Protein Kinase Inhibitors IGF1R, IGFBP1, IRS1 KMT2A 3494/4885MEN1 1660/4885MAPK10 375/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.